Logos Biopharma Advisors

Logos Biopharma Advisors is a boutique life sciences consulting firm that navigates complex drug development, asset and portfolio decisions. It helps organizations shape the development path around the science, translating emerging evidence into strategic choices that advance the asset and unlock value.

Founded by an accomplished drug developer Spyros Stamatelos, PhD, Logos brings decades of combined experience at the intersection of science, drug development, portfolio strategy and execution underpinned by deep expertise in translational pharmacology and end-to-end clinical development.

At Logos we believe the most consequential development decisions require more than data. They require the ability to integrate biology, pharmacology, clinical evidence, translational quantitative modeling and strategic context into a coherent decision framework.

We combine scientific rigor, quantitative insight and real-world drug-development experience to help teams interpret complex evidence, anticipate risk, and make decisions that withstand scientific, clinical, regulatory, and investor scrutiny.

When a program requires additional capabilities, Logos draws on a trusted network of experienced collaborators and subject-matter experts spanning drug development disciplines and therapeutic areas.

We partner with start-ups, emerging biotechnology companies, and investors to make critical development and investment decisions with greater clarity and confidence.

Drug Development Strategy:

Build integrated development strategies from translational planning through clinical proof of concept and beyond, including development pathways, regulatory strategy, indication strategy, and critical value-inflection points.

Quantitative & Clinical Pharmacology:

Integrate PK/PD, exposure-response, popPK, mechanistic and other MIDD approaches to guide dose selection, optimization, clinical study design and broader development strategy.

Scientific & Investment Diligence:

Evaluate assets and programs through a mechanistic, quantitative, and development-focused lens—assessing scientific rationale, translational confidence, clinical feasibility, development risk, competitive differentiation, and value-creation potential.

Our mission is to translate strong science into disciplined strategy and confident decisions - enabling organizations to select the right assets, design the right programs and invest wisely.